Table 2.
Characteristics of women who reported pregnancy after hematopoietic-cell transplantation
| Characteristic | Malignant diseases |
Non-Malignant diseases N (%) | ||
|---|---|---|---|---|
| Autologous N (%) | Allogeneic Myeloablative N (%) | Allogeneic Non-Myeloablative N (%) | ||
| Number of patients | 20 | 12 | 2 | 49 |
| Median age at HCT (range), years | 22 (16-33) | 21 (9-33) | (24-33) | 18 (5-32) |
| Age at HCT, years | ||||
| <10 | 0 | 2 (17) | 0 | 3 (6) |
| 10-19 | 8 (40) | 3 (25) | 0 | 26 (53) |
| 20-29 | 8 (40) | 6 (50) | 1 | 19 (39) |
| 30-39 | 4 (20) | 1 (8) | 1 | 1 (2) |
| Diagnosis | ||||
| Acute myeloid leukemia‡ | 2 (10) | 4 (33) | 0 | 0 |
| Acute lymphoblastic leukemia‡ | 0 | 4 (33) | 0 | 0 |
| Chronic myeloid leukemia | 0 | 3 (25) | 0 | 0 |
| Myelodysplastic syndrome | 0 | 1 (8) | 0 | 0 |
| Lymphoma | 18 (90) | 0 | 0 | 0 |
| Multiple myeloma | 0 | 0 | 1 | 0 |
| Severe aplastic anemia | 0 | 0 | 0 | 45 (92) |
| Immune deficiency disorder | 0 | 0 | 0 | 1 (2) |
| Other† | 0 | 0 | 1 | 3 (6) |
| Chemotherapy pre-HCT | 20 (100) | 11 (92) | 2 | 45 (92) |
| Radiation therapy pre-HCT | 10 (100) | 0 | 0 | 0 |
| Year of HCT | ||||
| ≤1989 | 0 | 2 (17) | 0 | 8 (16) |
| 1990-1994 | 7 (35) | 3 (25) | 0 | 9 (18) |
| 1995-1999 | 7 (35) | 6 (50) | 0 | 15 (31) |
| ≥2000 | 6 (30) | 1 (8) | 2 | 17 (35) |
| Conditioning regimen | ||||
| TBI + Cyclophosphamide ± Other | 0 | 9 (75) | 0 | 4 (8) |
| Busulfan + Cyclophosphamide ± Other | 1 (5) | 3 (25) | 0 | 1 (2) |
| Cyclophosphamide ± Other (no TBI or Busulfan) | 15 (75) | 0 | 0 | 43 (88) |
| Other | 4 (20) | 0 | 2 | 1 (2) |
| TBI in conditioning | ||||
| Median dose (range), cGy | - | 1200 (500-1440) | - | 200 (200-300) |
| TBI dose, cGy | ||||
| No TBI | 20 | 3 (25) | 2 | 45 (94) |
| <400 | 0 | 0 | 0 | 3 (6) |
| 400-800 | 0 | 1 (8) | 0 | 0 |
| >800 | 0 | 8 (67) | 0 | 0 |
| Missing | 0 | 0 | 0 | 1 |
| Cyclophosphamide dose, mg/kg | ||||
| No cyclophosphamide | 4 (20) | 0 | 2 | 1 (2) |
| ≤120 | 4 (20) | 7 (58) | 0 | 4 (8) |
| >120 | 12 (60) | 5 (42) | 0 | 43 (90) |
| Missing | 0 | 0 | 0 | 1 |
| Donor type | ||||
| Autologous | 20 | 0 | 0 | 0 |
| HLA-matched Siblings | 0 | 9 (75) | 2 | 42 (86) |
| Other related | 0 | 1 (8) | 0 | 1 (2) |
| Unrelated donor | 0 | 2 (17) | 0 | 6 (12) |
| Acute GVHD at any time after HCT | - | 6 (50) | 0 | 6 (12) |
| Chronic GVHD at any time after HCT | - | 5 (42) | 0 | 10 (20) |
| Relapse after HCT* | 1 (5) | 1 (8) | 1 | - |
| Median time from HCT to relapse, months | 36 | 1 | 3 | |
| Second transplant or DLI for relapse | 0 | 0 | 1 | 5 (10) |
| Disease status at last followup | ||||
| Continued complete remission | 19 (95) | 11 (92) | 1 | 0 |
| Complete remission after relapse | 0 | 1 (8) | 0 | 0 |
| Recurrent disease | 1 (5) | 0 | 1 | 0 |
| Cured | 0 | 0 | 0 | 48 (100) |
| Missing | 0 | 0 | 0 | 1 |
| Median followup (range), years | 9 (3-15) | 10 (5-20) | (3-4) | 9 (1-23) |
HCT – hematopoietic-cell transplantation, TBI – total body irradiation, GVHD – graft versus host disease, DLI – donor lymphocyte infusion
‡
4/6 patients with acute myeloid leukemia and 1/4 patients with acute lymphoblastic leukemia had received HCT in first complete remission
†
Includes chronic lymphocytic leukemia (N=1), thalassemia (N=1) and histiocytic disorders (N=2)
*
For malignant diseases only